News Gilead Sciences, Inc.

Stocks

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-21 EDT			5-day change	1st Jan Change
153.57 ^USD	-1.88%		+0.02%	+25.12%

12:15pm	Gilead's Biktarvy Pricing Impact Likely Manageable, RBC Says	MT
10-19	Gilead Sciences, Inc. Presents New Findings From Its HIV And Antiviral Research And Development Programs At IDWeek 2026	CI

All News

Mentions Relevance

12:15pm	Gilead's Biktarvy Pricing Impact Likely Manageable, RBC Says	MT
10-19	Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026	BU
10-19	Gilead Sciences, Inc. Presents New Findings From Its HIV And Antiviral Research And Development Programs At IDWeek 2026	CI
10-19	Gilead's pill succeeds in mid-stage bowel disease trial	RE
10-19	Gilead Sciences : Phase 2 SWIFT Study of Emvistegrast, a Potential Differentiated Once-daily Oral Treatment, Meets Primary Endpoint in Ulcerative Colitis	PU
10-16	Gilead Sciences Insider Sold Shares Worth $468,660, According to a Recent SEC Filing	MT
10-16	Gilead Sciences Insider Sold Shares Worth $468,660, According to a Recent SEC Filing	MT
10-15	Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026	BU
10-15	Goldman Sachs Adjusts Price Target on Gilead Sciences to $142 From $135	MT
10-14	Vir Biotechnology Shares Jump on Gilead Cancer Collaboration	DJ
10-14	Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal	RE
10-12	Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says	MT
10-12	BofA Securities Adjusts Gilead Sciences Price Target to $168 From $162, Maintains Buy Rating	MT
10-08	RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating	MT
10-07	Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences	AQ
10-07	Morgan Stanley Adjusts Price Target on Gilead Sciences to $163 From $165	MT
10-07	JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160	MT
10-06	Cognizant, Gilead Sign 5-Year Tech Extension Covering DevOps, AI Tools	MT
10-05	Nurix Therapeutics, Gilead Sciences Agree on Two-Year Research Term Extension for Oncology Program	MT
09-28	Mirum's liver infection drug lowers virus levels in late-stage study	RE
09-25	HEALTH ROUNDS-Genetic discovery yields clues toward reversal of Alzheimer's brain damage	RE
09-23	Hackensack Meridian Center for Discovery and Innovation, Gilead Sciences and the Rockefeller University Collaborate to Research Oral Treatments for Mosquito-Borne Flaviviruses	CI
09-18	Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF	AQ
09-16	Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing	MT
09-16	Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited	CI